Vol. 17/No. 9 | OncologyLive

Dalla-Favera’s Research Sets Stage for Lymphoma Advances

May 03, 2016

Riccardo Dalla-Favera, MD, whose work has helped characterize the molecular drivers of B-cell lymphomas, was honored in the Lymphoma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Emerging Antiemetics Offer More Complete Control of Debilitating CINV

April 28, 2016

The new generation of drugs that have emerged as part of antiemetic cocktails have demonstrated greater success in preventing and controlling CINV but the symptoms still present significant obstacles in anticancer therapy.

Genomics Studies Opening Up Fresh Options for CRC Research

April 22, 2016

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

Acalabrutinib Challenges Ibrutinib in High-Risk CLL Trial

April 22, 2016

Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).

Trouble Behind the Scenes

April 21, 2016

The cascade of news about cancer research—whether it’s about a new drug, biomarker, or treatment approach—has become an ever-present feature of the oncology landscape